Aptamer Group plc (AIM: APTA), the York-based developer of next-generation synthetic Optimer® binders, has announced the posting of its Annual Report and Accounts for the year ended 30 June 2026, alongside a Notice of its 2026 Annual General Meeting. The AGM is scheduled for 11.00 am GMT on Wednesday, 16 December 2026, at the company's headquarters at Windmill House, Innovation Way, York. The announcement confirms the meeting will be held in person only, with no new information to be presented, making the subsequent voting results the key event for investors to monitor.
Key Points
- Aptamer Group plc (AIM: APTA) — AIM-listed developer of synthetic Optimer® binders, headquartered in York, UK
- Annual Report and Accounts for the year ended 30 June 2026 posted to shareholders on 17 November 2026
- AGM to be held in person at Windmill House, York, on 16 December 2026 at 11.00 am GMT
- Investors should watch for AGM voting results, to be announced to the London Stock Exchange after the meeting concludes
Aptamer Group's Annual Report and 2026 AGM Notice Despatched to Shareholders
Aptamer Group confirmed on 17 November 2026 that both the Annual Report and Accounts for the financial year ended 30 June 2026 and the formal Notice of the 2026 AGM have been posted to shareholders. Both documents are also available on the company's investor relations website. The AGM will be conducted on a fully in-person basis, with the company explicitly confirming that no new information will be presented at the meeting. Voting results across all resolutions will be reported to the London Stock Exchange and published on the company's website as soon as practicable following the conclusion of the meeting.
Optimer® Platform and Dual-Revenue Model Underpin Aptamer's Commercial Strategy
Aptamer Group develops Optimer® binders — proprietary synthetic alternatives to antibodies designed to offer high specificity, improved stability, lower cost, and access to biological targets beyond the reach of conventional modalities. The group operates a dual-revenue model, generating near-term income through fee-for-service discovery programmes whilst simultaneously building a portfolio of proprietary therapeutic assets intended to deliver long-term value via licensing, royalties, and supply agreements. The company states its Optimer® platform is supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine.
Internal Pipeline Targets Oligonucleotide Delivery and Radioligand Therapy Programmes
The company's internal pipeline focuses on two areas it identifies as significant challenges in modern drug development: targeting so-called "undruggable" proteins and enabling therapeutic delivery to tissues beyond the liver. Its pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes. Upcoming in vivo studies are described in the announcement as expected to support future partnering and licensing opportunities. Founded in 2008, Aptamer works with a number of leading pharmaceutical companies globally, combining platform expertise with proprietary data to pursue these programmes.
AGM Resolutions and Post-Meeting Disclosure to Be Watched by APTA Investors
Because the company has confirmed no new information will be shared at the 16 December AGM itself, investor attention is likely to focus on the formal voting outcomes, which will be disclosed to the London Stock Exchange after the meeting. The AGM is being held at Windmill House, Innovation Way, York, YO10 5BR, and attendance is restricted to in-person participants only. Shareholders unable to attend in person should refer to the posted AGM Notice for proxy voting procedures. The full voting results will subsequently be published on the Aptamer Group investor relations website.




Please wait processing your request...